Sienna Biopharmaceuticals (Sienna Biopharmaceuticals) Change In Receivables : $0.00 Mil (TTM As of Sep. 2019)

View and export this data going back to 2017. Start your Free Trial

What is Sienna Biopharmaceuticals Change In Receivables?

Sienna Biopharmaceuticals's change in receivables for the quarter that ended in Sep. 2019 was $0.00 Mil. It means Sienna Biopharmaceuticals's Accounts Receivable stayed the same from Jun. 2019 to Sep. 2019 .

Sienna Biopharmaceuticals's change in receivables for the fiscal year that ended in Dec. 2018 was $0.00 Mil. It means Sienna Biopharmaceuticals's Accounts Receivable stayed the same from Dec. 2017 to Dec. 2018 .

Sienna Biopharmaceuticals's Accounts Receivable for the quarter that ended in Sep. 2019 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Sienna Biopharmaceuticals's liquidation value for the three months ended in Sep. 2019 was $-9.06 Mil.

Sienna Biopharmaceuticals Change In Receivables Historical Data

The historical data trend for Sienna Biopharmaceuticals's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sienna Biopharmaceuticals Change In Receivables Chart

Sienna Biopharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Change In Receivables

Sienna Biopharmaceuticals Quarterly Data
	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19
Change In Receivables	Get a 7-Day Free Trial											-	-	-	-	-

Sienna Biopharmaceuticals Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Sep. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Sienna Biopharmaceuticals (OTCPK:SNNAQ) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Sienna Biopharmaceuticals's Days Sales Outstanding for the quarter that ended in Sep. 2019 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Sienna Biopharmaceuticals's accounts receivable are only considered to be worth 75% of book value:

Sienna Biopharmaceuticals's liquidation value for the quarter that ended in Sep. 2019 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	11.332	-	20.391	+	0.75 * 0	+	0.5 * 0
=	-9.06

Sienna Biopharmaceuticals Change In Receivables Related Terms

Thank you for viewing the detailed overview of Sienna Biopharmaceuticals's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Sienna Biopharmaceuticals (Sienna Biopharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sienna Biopharmaceuticals Inc (OTCPK:SNNAQ) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

30699 Russell Ranch Road, Suite 140, Westlake Village, CA, USA, 91362

Website

http://www.SiennaBio.com

Sienna Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on bringing innovations in biotechnology to the discovery, development, and commercialization of first-in-class, targeted, topical products in medical dermatology and aesthetics. The objective is to develop multi-asset pipeline of topical therapies that enhance the health, appearance, and quality of life of dermatology patients. The product portfolio includes SNA-120, SNA-125, and SNA-001.

Executives

Alexander Azoy	officer: Chief Financial Officer	30699 RUSSELL RANCH ROAD, SUITE 140, WESTLAKE VILLAGE CA 91362
Timothy K. Andrews	officer: General Counsel & Secretary	30699 RUSSELL RANCH ROAD, SUITE 140, WESTLAKE VILLAGE CA 91362
Iii Frederick Beddingfield	director, officer: President & CEO	C/O KYTHERA BIOPHARMACEUTICALS, INC. 27200 WEST AGOURA ROAD, SUITE 200 CALABASAS CA 91301
Paul F. Lizzul	officer: Chief Medical Officer	30699 RUSSELL RANCH ROAD, SUITE 140, WESTLAKE VILLAGE CA 91362
Diane Stroehmann	officer: See Remarks	30699 RUSSELL RANCH ROAD SUITE 140 WESTLAKE VILLAGE CA 91362
Dennis M Fenton	director
Todd Harris	director	30699 RUSSELL RANCH ROAD, SUITE 140, WESTLAKE VILLAGE CA 91362
Kristina Burow	director, 10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Robert J More	director	680 S CACHE STREET, SUITE 100, BOX 10820, JACKSON WY 83001
James M. Hindman	director	2525 DUPONT DRIVE, IRVINE CA 92612
Keith R Leonard	director	ARYX THERAPEUTICS,INC., 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Arch Venture Partners Viii, L.p.	10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Fund Viii Overage, L.p.	10 percent owner	C/O ARCH VENTURE PARTNERS VIII, LLC, 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Fund X Overage, L.p.	10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Partners X Overage, L.p.	10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631